CRYOPDP

How do you reorganise an urgent clinical trial shipment without losing control? When a collection time changes or a flight is cancelled, booking the next available option is only part of the answer. The revised plan still needs to meet the delivery window, maintain the required temperature and keep the documentation and chain of custody intact. CRYOPDP reviews the time available, the new route, the packaging performance and the available transport options before putting another plan in place. We then coordinate the revised collection, handovers and delivery with the sites and teams involved, making sure everyone has the information they need. Giving clinical trial teams a workable alternative when the original plan changes, without compromising shipment requirements or creating further delays for the study. Know more about our clinical trial logistics solutions here: https://lnkd.in/dJ_N-gRh #ClinicalTrials #ClinicalTrialLogistics #ClinicalResearch #TimeCriticalLogistics #TemperatureControlledLogistics #ClinicalSupplyChain #PharmaLogistics #LifeSciences #CRYOPDP

Can adding immunotherapy help TACE hold back liver cancer for longer? The Phase III EMERALD-3 trial included 760 patients with intermediate-stage hepatocellular carcinoma across 171 institutions in 22 countries. Adding durvalumab, tremelimumab and lenvatinib to TACE extended median progression-free survival from 9.8 to 13 months. Overall survival results are still emerging, and serious side effects were more common with the combination, so the balance between benefit and tolerability will remain important as the study continues. A treatment like this can easily become three separate medicine supply chains around one patient. CRYOPDP brings them into one operation, so sites are not left managing separate ordering, storage and delivery processes for each drug used alongside TACE. Read the full story from Memorial Sloan Kettering Cancer Center: https://lnkd.in/dbmatHBK. #CRYOPDP #LiverCancer #ClinicalTrials #Immunotherapy #HepatocellularCarcinoma #CancerResearch #ClinicalSupply #Oncology #LifeSciences

What happens when a patient is in remission, but the test still shows cancer cells? A Phase II study at MD Anderson tested inotuzumab ozogamicin in 37 patients with B-cell acute lymphoblastic leukaemia who had measurable residual disease after previous treatment. The therapy cleared the remaining cancer cells in 70% of patients. Relapse-free survival reached 40 months, while median overall survival was 61 months. The strongest outcomes were seen when treatment was given earlier. That matters because achieving MRD negativity can lower the risk of relapse and may allow some patients to proceed to stem cell transplant or CAR T-cell therapy with less disease present. MRD results can change treatment decisions before a relapse is visible. In trials built around that result, CRYOPDP manages depot stock, treatment orders and delivery to site once eligibility is confirmed, rather than supplying every patient according to a fixed calendar. Read the full story from MD Anderson: https://lnkd.in/ebK2UuuP. #CRYOPDP #Leukemia #BCellALL #ClinicalTrials #CancerResearch #MRD #AntibodyDrugConjugate #ClinicalSupply #Oncology

Could 12 weeks of treatment be sufficient for some people with HER2-positive breast cancer? The Phase II DAPHNe trial followed 98 patients with stage II or III disease who received paclitaxel, trastuzumab and pertuzumab before surgery. Five years later, event-free survival was 99%, with no distant recurrences reported. Among patients with detectable ctDNA at baseline, 96.1% cleared it after the 12-week treatment period. These findings do not mean treatment should be reduced yet, but they strengthen the case for studying whether response and ctDNA can identify patients who may safely avoid unnecessary therapy. A trial asking whether some patients can receive less treatment cannot plan supply as though everyone will need the same amount. CRYOPDP adjusts stock as treatment decisions are made and brings unused product back from sites, rather than leaving excess inventory unused. Read the full research update from Dana-Farber: https://lnkd.in/eGA5nUsr. #CRYOPDP #BreastCancer #HER2Positive #ClinicalTrials #CancerResearch #ctDNA #PrecisionMedicine #ClinicalSupply #Oncology

Why do some life sciences shipments need white-glove handling? Sensitive, high-value or difficult-to-replace materials cannot always be handled through a routine collection and delivery process. Customers need to know who is responsible for the shipment, how each handover will be managed and what will happen if the original plan changes. For each shipment, the route, temperature range, delivery window and handling instructions are agreed in advance, with CRYOPDP managing the journey, handling any changes and keeping the customer informed throughout. Giving the customer one point of contact and closer control over shipments that need extra attention from collection through to final delivery. Know more about our White-Glove Service here: https://lnkd.in/e9gHCsvF. #WhiteGloveLogistics #WhiteGloveService #LifeSciencesLogistics #HealthcareLogistics #TemperatureControlledLogistics #HighValueShipments #ChainOfCustody #ProductIntegrity #CRYOPDP

What does another treatment option mean when several others have already failed? A Phase I trial is testing ozekibart with FOLFIRI chemotherapy in people with advanced colorectal cancer who have already received two or three previous treatments. Among 45 evaluable patients, tumours shrank in 20%, and 87% saw their disease shrink or remain stable. One patient had no visible tumour on their scan. These are early results from a small, non-randomised study, but they offer something important to patients who have very few options left. Early trials often work with limited investigational stock and small patient groups. CRYOPDP manages that supply from depot storage to site delivery and return, with every vial accounted for throughout the study. Read the full story from The Institute of Cancer Research: https://lnkd.in/eRqe4Vjn. #CRYOPDP #ColorectalCancer #ClinicalTrials #CancerResearch #Oncology #TargetedTherapy #EarlyPhaseTrials #ClinicalSupply #PatientCare

Could people with Lynch syndrome one day be vaccinated before cancer has a chance to develop? The INTERCEPT-Lynch trial has been approved to test mRNA-4194, an investigational vaccine for people with an inherited condition that can raise lifetime cancer risk to as much as 80%. Rather than treating an existing tumour, the vaccine is designed to help the immune system recognise and remove pre-cancerous cells before cancer develops. The first phase is expected to begin recruiting in Oxford this summer to assess safety, immune response and the dose to take forward. More UK centres are planned for 2027. Prevention trials involve people who may feel completely well but live with a much higher risk of cancer. CRYOPDP helps sponsors shape trial supply around their scheduled visits, making sure the vaccine is stored, prepared and delivered under the conditions the study requires, without adding unnecessary difficulty for participants. Read the full story from the University of Oxford: https://lnkd.in/eCB3dU3P. #CRYOPDP #CancerPrevention #LynchSyndrome #MRNAVaccine #ClinicalTrials #CancerResearch #PrecisionMedicine #ClinicalSupply #Oncology

When you move sensitive materials across borders, you often face different customs rules, airport procedures, and delivery requirements at each step. CRYOPDP connects all these stages through a single global network, so you do not need to manage multiple providers or worry about gaps when your shipment changes hands. Know more about us: https://lnkd.in/dWhQjPnF #GlobalNetwork #LifeSciencesLogistics #InternationalShipping #HealthcareLogistics #CRYOPDP

Could treating high-risk prostate cancer before and after surgery give patients more time before the disease spreads? The Phase III PROTEUS trial included 2,109 men with high-risk localised or locally advanced prostate cancer across 18 countries. Patients received apalutamide with androgen deprivation therapy before and after radical prostatectomy. The treatment produced a ninefold improvement in complete or near-complete pathological response and reduced the risk of metastasis or death by 20%. It also extended the median time before another treatment was needed from 41.5 to 74.2 months. Grade 3 or 4 treatment-related side effects were more common with apalutamide, although the overall safety profile was considered manageable. PROTEUS ran through the COVID-19 pandemic, and PSMA PET imaging was also added to the protocol. Long trials do not happen in a fixed world. CRYOPDP helps sponsors reshape depot coverage, routes and site supply when the study changes, without passing that disruption on to the clinical sites. Read the full story from UroToday: https://lnkd.in/e9awsnWy. #CRYOPDP #ProstateCancer #ClinicalTrials #Oncology #CancerResearch #ClinicalSupply #GlobalTrials #LifeSciences #PatientOutcomes

When platinum stops working, what can a different target change? The first patient has been enrolled in BEHOLD-Ovarian01, a global phase 3 trial evaluating mocertatug rezetecan for platinum-resistant ovarian cancer. The study will compare the B7-H4-targeted antibody-drug conjugate with the standard of care to see whether it can improve outcomes for patients whose cancer no longer responds to platinum treatment. The trial follows encouraging activity observed in the phase 1 BEHOLD-1 study, but there are no phase 3 results yet. With enrolment opening at multiple centres and every patient starting treatment on a different timetable, CRYOPDP gives trial teams a single connected view of what is available, where it is needed next, and when the temperature-controlled shipment must move. Read the full press release: https://lnkd.in/e3neda_p. #OvarianCancer #PlatinumResistantOvarianCancer #GynecologicOncology #AntibodyDrugConjugate #B7H4 #Phase3Trial #CancerResearch #ClinicalTrialLogistics #CRYOPDP